GlaxoSmithKline Plc has entered into a four-year contract with an arm of the US government to supply the monoclonal anti-toxin, raxibacumab, for stockpiling against a potential bioterrorist attack. The contract has a value of about $196 million. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals